New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:47 EDTEPZMEpizyme price target raised to $52 from $37 at Wedbush
Wedbush increased its price target on Epizyme after the company released clinical data on its EPZ-5676 treatment that the firm views as positive. The firm reiterates an Outperform rating on the stock.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
08:30 EDTEPZMEpizyme announces notice of allowance for U.S. patent applications
Epizyme announced that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled “PRMT5 Inhibitors and Uses Thereof.” The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers. Epizyme also announced the publication of 10 patent applications covering chemical matter targeting several additional HMTs: CARM1, PRMT1, PRMT3, PRMT6 and PRMT8. These additional HMT targets are implicated in a variety of solid tumors and hematologic malignancies.
October 17, 2014
08:05 EDTEPZMEpizyme presents EPZ-6438 pre-clinical data
Subscribe for More Information
October 10, 2014
08:02 EDTEPZMEpizyme announces presentation of EPZ-6438, EPZ-5676 data
Epizyme announced that clinical and pre-clinical data on its histone methyltransferase inhibitors will be highlighted in oral and poster presentations at the 56th annual meeting of the American Society of Hematology to be held December 6-9 in San Francisco, California. The company will present data from EPZ-5676 and EPZ-6438 studies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use